The mTOR inhibitor, CCI-779, is effective against myeloma growth in vivo.

被引：0
|
作者：
Frost, P [1 ]
Gera, J [1 ]
Shi, YJ [1 ]
Lichtenstein, A [1 ]
机构：
[1] Univ Calif Los Angeles, W LA VA Med Ctr, Los Angeles, CA USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1626
引用
收藏
页码：445A / 445A
页数：1
相关论文
共 50 条
  • [1] In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
    Frost, P
    Moatamed, F
    Bai, H
    Shi, YJ
    Gera, J
    Yan, HJ
    Frost, P
    Gibbons, J
    Lichtenstein, A
    [J]. BLOOD, 2004, 104 (13) : 4181 - 4187
  • [2] Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients
    Peralba, JM
    DeGraffenried, L
    Friedrichs, W
    Fulcher, L
    Grünwald, V
    Weiss, G
    Hidalgo, M
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (08) : 2887 - 2892
  • [3] Temsirolimus: CCI 779, CCI-779, Cell cycle inhibitor-779
    不详
    [J]. Drugs in R & D, 2004, 5 (6) : 363 - 367
  • [4] Temsirolimus (CCI-779): Early results of an mTOR inhibitor in renal carcinoma
    Hudes, GR
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 18 - 18
  • [5] Effects of mTOR inhibitor, rapamycin and the ester analogue CCI-779 on rhabdomyosarcoma.
    Wan, XL
    Kalburgi, S
    Heiman, L
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6179S - 6179S
  • [6] In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer
    Ito, D
    Fujimoto, K
    Mori, T
    Kami, K
    Koizumi, M
    Toyoda, E
    Kawaguchi, Y
    Doi, R
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (09) : 2337 - 2343
  • [7] LENALIDOMIDE AND CCI-779 TREATMENT FOR RELAPSED MULTIPLE MYELOMA
    不详
    [J]. CANCER DISCOVERY, 2011, 1 (04) : 283 - 283
  • [8] The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
    Teachey, DT
    Obzut, DA
    Cooperman, J
    Fang, JJ
    Carroll, M
    Choi, JK
    Houghton, PJ
    Brown, VI
    Grupp, SA
    [J]. BLOOD, 2006, 107 (03) : 1149 - 1155
  • [9] mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
    Yu, K
    Toral-Barza, L
    Discafani, C
    Zhang, WG
    Skotnicki, J
    Frost, P
    Gibbons, JJ
    [J]. ENDOCRINE-RELATED CANCER, 2001, 8 (03) : 249 - 258
  • [10] Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition
    Dudkin, L
    Dilling, MB
    Cheshire, PJ
    Harwood, FC
    Hollingshead, M
    Arbuck, SG
    Travis, R
    Sausville, EA
    Houghton, PJ
    [J]. CLINICAL CANCER RESEARCH, 2001, 7 (06) : 1758 - 1764
12345